ANMAT and INPM: The Regulatory Authorities for Medical Devices in Argentina

1. Key takeaways

The regulatory authority for medical devices in Argentina is the National Administration of Drugs, Foods and Medical Technology (ANMAT). However, the executive layer that companies actually deal with on a day-to-day basis is its subordinate institute, the National Institute of Medical Products and Technology (INPM) — classification determination, technical review and registration are all carried out by the INPM, while post-market surveillance is handled by a separate line, the Directorate of Post-Market Surveillance and Regulatory Action (DVPCyAR). Understanding this division of labor is the first step in any Argentine filing, because it determines who reviews your dossier and who answers your questions.

Companies must simultaneously satisfy four mutually independent regulatory lines: company establishment authorization (habilitación), product registration (registro), good manufacturing practice (BPF/GMP), and post-market technovigilance. These four lines correspond respectively to Disposición ANMAT 2319/2002, Disposición ANMAT 64/2025, Disposición ANMAT 3266/2013 and Disposición ANMAT 8194/2023. If any one of the four is missing, the sale of the product in Argentina lacks a lawful basis entirely. This is the most fundamental difference between the Argentine regulatory architecture and most single-registration markets: obtaining a product certificate alone is never sufficient to sell legally.

A practical consequence follows immediately. Because the four lines are independent, each must be planned, resourced and tracked as its own project workstream, with its own evidence package and its own responsible owner. Teams that treat registration as the only milestone routinely discover late that they cannot lawfully import or market the product until the remaining three are also in place, and the resulting schedule slip is entirely avoidable with upfront planning.

2. Legal basis

The following instruments jointly define the institutional structure described above, from the parent act through the ANMAT founding decree to the four operative disposiciones that companies must comply with in parallel.

3. Expert insights

Insight one: the institution is the same, but the receiving windows differ. Documents submitted to ANMAT in fact travel along a three-stage path: window intake — INPM technical review — entry into the register. This means that deficiency responses are addressed to the INPM reviewers, not to the ANMAT external window. Addressing communication to the wrong counterpart directly lengthens the response cycle, because every misdirected submission must be re-routed internally before review can resume.

Insight two: there is no primary-versus-secondary hierarchy among the four lines, and no serial triggering mechanism. Obtaining the product registration certificate does not automatically confer company authorization, and holding company authorization does not exempt the product from registration. The two can be pursued in parallel, but company establishment authorization is a precondition for product registration — the applicant must be a local company already authorized by ANMAT. In practice, a mismatch between the timelines of company authorization and product registration is the most common source of schedule delay, and it is also the least predictable one, because the two procedures are administered under different rules and workload queues.

Insight three: the RPPTM/RPPTMI registers are public credentials whose legality can be verified. Once a certified product is entered into the register of medical products and technology, its registration number can be checked through public channels. For purchasers, this is the direct means of verifying supplier credentials; for manufacturers, the accuracy of the registration information is equivalent to market reputation. Any discrepancy between the register entry and the product actually marketed — indications, models, manufacturer details — is a compliance exposure that competitors, distributors and authorities can all discover with a simple lookup.

4. Practical recommendations

1. First confirm the authorization type of your local partner. The Argentine local company you intend to engage must hold a manufacturing and/or import establishment authorization under Disposición 2319/2002, and the scope of that authorization must cover the risk class of the products to be filed. Before signing, require the partner to present the original authorization certificate issued by ANMAT and verify its validity period.
2. Lay the four lines out on a single Gantt chart. Set an independent owner and start/end milestones for each of the four items — company authorization, product registration, GMP evidence and the vigilance system — and avoid the pattern of waiting for the certificate before building the system.
3. Fix ownership of official communication channels in the agreement. The agreement with the certificate holder should expressly state who holds all correspondence with ANMAT/INPM, deficiency notices and system accounts; this determines whether the certificate can later be transferred smoothly.
4. Build a registration number ledger that is externally verifiable. After certification, synchronize the registration numbers into the product catalog, distributor training materials and tender documents, reducing downstream verification costs for everyone in the supply chain.

5. Verification checklist

• □ Confirmed that the regulatory authority is ANMAT, the executive layer is the INPM, and vigilance belongs to the DVPCyAR
• □ Verified that the local partner holds a valid establishment authorization under Disposición 2319/2002
• □ Checked that the authorization scope covers the risk class of the products to be filed
• □ Built a timeline covering company authorization, product registration, GMP and vigilance
• □ Specified in the agreement who holds the ANMAT system accounts and official correspondence
• □ Planned how registration numbers will be verified in the HELENA public database after certification

Regulatory information verified as of October 29, 2026.

In Argentina, GRZAN operates a wholly owned subsidiary that can act as the registration holder and importer for foreign manufacturers, directly undertaking classification determination, pathway selection, GMP and CFS documentation chains, Spanish-language localization of technical documentation and labels, HELENA submissions and deficiency responses, as well as BONITA import notifications, operation of the ARGOS vigilance system, change maintenance and 5-year renewal planning.

The GRZAN regulatory team consists of professionals with many years of hands-on international registration experience and continuously tracks the developments of regulatory authorities worldwide; all published content follows the editorial standard of conclusions first, traceable bases and verifiable figures. For a tailored market access plan for Argentina or the MERCOSUR region covering a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.